Sarissa Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sarissa Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$161K	–	12
2021 Q2	$161K	Hold	1,000	–	–	0.01%	13
2021 Q1	$171K	Hold	1,000	–	–	0.02%	12
2020 Q4	$219K	Hold	1,000	–	–	0.02%	11
2020 Q3	$166K	Hold	1,000	–	–	0.02%	11
2020 Q2	$114K	Hold	1,000	–	–	0.01%	12
2020 Q1	$76K	Hold	1,000	–	–	0.01%	12
2019 Q4	$128K	Hold	1,000	–	–	0.01%	12
2019 Q3	$77K	Hold	1,000	–	–	0.01%	11
2019 Q2	$103K	Hold	1,000	–	–	0.01%	12
2019 Q1	$73K	Hold	1,000	–	–	0.01%	11
2018 Q4	$42K	Buy	+1,000	New	+$39.9K	0.01%	10

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sarissa Capital Management's MRTX Position: Q3 2021 in Review

Sarissa Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 1,000 shares — an estimated $161K sold.

Sarissa Capital Management first reported a position in MRTX in Q4 2018 and held it in 11 quarters. The position peaked at $219K in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Sarissa Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Sarissa Capital Management sold 1,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $161K.
Sarissa Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
Sarissa Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $219K in Q4 2020.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Sarissa Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.